{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:55:49Z","timestamp":1760147749659,"version":"build-2065373602"},"reference-count":14,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hodgkin lymphoma (HL) is traditionally considered one of the hematological malignancies with the highest rate of cure, ranging from 70 to 90% depending on the disease and patient features [...]<\/jats:p>","DOI":"10.3390\/jcm12051928","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T01:36:09Z","timestamp":1677634569000},"page":"1928","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances and Clinical Outcomes in Hodgkin Lymphoma in the Era of Novel Therapies"],"prefix":"10.3390","volume":"12","author":[{"given":"Annalisa","family":"Paviglianiti","sequence":"first","affiliation":[{"name":"Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, 08908 Barcelona, Spain"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2","family":"Rampi","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, 08908 Barcelona, Spain"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol. Off."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: A single centre, phase 1\/2 study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial","volume":"41","author":"Meissner","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/s41409-020-0929-y","article-title":"Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed\/refractory Hodgkin lymphoma: An analysis of the Lymphoma Working Party of the EBMT","volume":"55","author":"Sureda","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1928\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:44:48Z","timestamp":1760121888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12051928"],"URL":"https:\/\/doi.org\/10.3390\/jcm12051928","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}